Long-term efficacy but rare sustained remission: individual-level 5-year stability in anti-IL5/Rα biologic therapy response for severe asthma
Patients with severe asthma respond well to anti-IL5/Rα, with substantial improvements across all domains over 5 years. Remission is a dynamic state with intermittent relapses, and sustained long-term remission is rare using current domains.
Authors
- Barbara Bonnesen
- Anna von Bülow (ORCID: https://orcid.org/0009-0005-3268-785X)
- Marianne Baastrup Soendergaard (ORCID: https://orcid.org/0000-0002-4954-0863)
- Ole Hilberg (ORCID: https://orcid.org/0000-0002-3075-3463)
- Roxana Vijdea
- Susanne Hansen (ORCID: https://orcid.org/0000-0002-9550-6703)
- Sofie Lock Johansson (ORCID: https://orcid.org/0000-0003-0597-9468)
- Charlotte Suppli Ulrik (ORCID: https://orcid.org/0000-0001-8689-3695)
- Kjell Erik Julius Håkansson (ORCID: https://orcid.org/0000-0001-5804-0740)
- Johannes Martin Schmid (ORCID: https://orcid.org/0000-0002-4558-2943)
- Lycely Dongo
- Celeste Porsbjerg (ORCID: https://orcid.org/0000-0003-4825-9436)
- Claus Rikard Johnsen (ORCID: https://orcid.org/0009-0008-4149-4592)
- Anne‐Sofie Bjerrum (ORCID: https://orcid.org/0009-0002-1657-2399)
- Maria Bisgaard Borup
- Linda Makowska Rasmussen
Institutions
- Aalborg University Hospital (DK)
- Odense University Hospital (DK)
- Bispebjerg Hospital (DK)
- Hvidovre Hospital (DK)
- Aarhus University Hospital (DK)
- Gentofte Hospital (DK)
- Zealand University Hospital (DK)
- Vejle Sygehus (DK)
- Lillebaelt Hospital (DK)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1183/13993003.00926-2025
- Citations
- 3
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.49